Crizotinib (PF-02341066)

Licensed by Pfizer Catalog No.S1068

Crizotinib (PF-02341066) Chemical Structure

Molecular Weight(MW): 450.34

Crizotinib (PF-02341066) is a potent inhibitor of c-Met and ALK with IC50 of 11 nM and 24 nM in cell-based assays, respectively.

Size Price Stock Quantity  
In DMSO USD 220 In stock
USD 110 In stock
USD 170 In stock
USD 570 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 72 Publications

13 Customer Reviews

  • (c) Western blot analyses of p-Akt (Ser473) and p-S6RP (Ser235 and Ser236) in two RCT-E565 transplanted tumors treated with vehicle or PF02341066. Samples were isolated 4 h after the last dose from mice treated with PF02341066 for 3 d. (d) Responses of RCT-E565 transplanted tumors in athymic mice to PF02341066 or vehicle. Data are means ±s.e.m. (each group, n = 6). *P < 0.005, **P < 0.001 (Student,s t test).

    Nat Med 2011 17, 1116-1120. Crizotinib (PF-02341066) purchased from Selleck.

    Ba/F3 cells grown in the presence of IL-3, or Ba/F3 cells expressing native EML4-ALK (clone #2, #10, #101, and #155) and EML4-ALK L1196M (clone #216, #302, #303, and #355), were treated with CH5424802 or PF-02341066 for 48 hr, and then the viable cells were measured by the Cell Titer-Glo Luminescent Cell Viability Assay. IC50 values were determined by plotting the drug concentration versus percentage of cell growth inhibition. Data are shown as mean ±SD (n = 3).



    Cancer Cell 2011 19, 679–690. Crizotinib (PF-02341066) purchased from Selleck.

  • Mice bearing Ba/F3-EML4-ALK (clone #10) and EML4-ALK L1196M (clone #303) were administered vehicle, CH5424802 (60 mg/kg), or PF-02341066 (100 mg/kg) orally once daily for 8 days. Tumor volume for each dose group was measured. Data are shown as mean ± SD (n = 5). Parametric Dunnett’s test: ***p < 0.001; N.S., not significant, versus vehicle treatment at final day. For pharmacodynamic assay, mice bearing Ba/F3-EML4-ALK (clone #10) and -EML4-ALK L1196M (clone #303) were orally administered at single dose of vehicle, CH5424802 (60 mg/kg), or PF-02341066 (100 mg/kg), and the tumors were collected and lysed at 4 hr post-dosing. STAT3 and phosphorylated STAT3 (Tyr 705) were detected by immunoblot analysis using antibodies against each of them (n = 2 per group).



    Cancer Cell 2011 19, 679–690. Crizotinib (PF-02341066) purchased from Selleck.

    (A) Immunoblots of MPM cells treated with the indicated concentrations of crizotinib alone for 24 h with HGF stimulation.

    Sci Rep, 2016, 6:32992. Crizotinib (PF-02341066) purchased from Selleck.

  • Three MET amplified (Hs746t, SNU-5 and MKN45) and two non-amplified cell lines (MKN74 and NUGC-4) were incubated with or without 100nM crizotinib 24 hours, and total protein was extracted using RIPA lysis buffer. Total lysates were then analyzed by immunoblotting using anti-phospho-MET, anti-total-MET, and β-actin antibodies.

    Oncotarget, 2017, 8(31):51675-51687. Crizotinib (PF-02341066) purchased from Selleck.

    Viability of Ba/F3 cells stably expressing DCTN1-ALK or EML4-ALK cDNAs after treatment with crizotinib (C). Ba/F3 cells transduced with lentiviral cDNA or empty vector were subjected to the assay, and the number of cells was counted at 72 hours.

    Oncologist, 2017, 22(2):158-164. Crizotinib (PF-02341066) purchased from Selleck.

  • Combination of EGCG with c-MET inhibitor has enhanced inhibitory effects on the growth of OS cells. MG-63 and U-2OS cells were treated with crizotinib (0.05 mM) and/or EGCG (0.08 g/L) for 48 h, and the effects on cell apoptosis (b) were determined using flow cytometry. *P<0.05 versus the control; #P<0.05 versus crizotinib-treated groups or EGCG-treated groups

    Tumour Biol, 2016, 37(4):4373-82. Crizotinib (PF-02341066) purchased from Selleck.

    (A) VimPro-Fluc activity in spheroids after 72-h treatment with control modulators of epithelial-mesenchymal transition (EMT) normalized to spheroid viability and compared to vimentin protein expression using Western blot analysis. (B) Dose-response curves for both U0126 and axitinib control modulators of EMT. RLU, relative luminescence units.

    J Biomol Screen 2011 16, 141-154. Crizotinib (PF-02341066) purchased from Selleck.

  • Secondary assay development. The invasive potential of MDA-MB-231 spheroids was measured using modified Boyden chambers coated with Matrigel™. Invading cells were fixed, stained with DAPI, and quantified by fluorescence microscopy using 5 random fields per filter insert in triplicate. U0126, PF2341066, axitinib, and PKC412 inhibited the invasive potential of MDA-MB-231 spheroids by ~90% as compared to untreated spheroids (UT). ***p ≤ 0.001. IGF1R and dasatinib displayed no statistical difference as compared to UT MDA-MB-231 spheroids.

    J Biomol Screen 2011 16, 141-154. Crizotinib (PF-02341066) purchased from Selleck.

    Crizotinib impaired tumor vascularization. a-e Representative photomicrographs (40×) of CD31 staining in negative control and indicated LFD, HFD, vehicle (veh) and crizotinib (criz) treated groups. b CD31 was quantified on 5–6 randomly selected regions of n = 2 sections each from each mouse. N = 9–10 mice (a vs b, Veh vs Criz, P = 0.0138)

    Springerplus, 2016, 5:348. Crizotinib (PF-02341066) purchased from Selleck.

  • Inhibition of signaling pathway activation in lung tumor cell lines by kinase inhibitors. Lung tumor cells were cultured in 10% FBS until reaching ∼80% confluence and then the cells were starved in serum-free medium for overnight, followed by 4-hour treatment with the inhibitors. Cell lysates were then prepared and used for determination of the pathway activation signals by the CEER assay.

    Int J Proteomics 2011 2011, 215496. Crizotinib (PF-02341066) purchased from Selleck.

    Inhibition of anchorage-independent growth of lung tumor cell lines by selected inhibitors. Each selected cell line was treated with the indicated inhibitor at 0.1 μM and 1 μM concentrations for two weeks and cell colony size formation was scored under the Nikon inverted-phase microscope.

    Int J Proteomics 2011 2011, Article ID 215496. Crizotinib (PF-02341066) purchased from Selleck.

  • Western blot analysis of c-Met, MAPK and Akt. 0-100nM PF2341066 was added.



    Dr. Zhang of Tianjin Medical University. Crizotinib (PF-02341066) purchased from Selleck.

Purity & Quality Control

Choose Selective c-Met Inhibitors

Biological Activity

Description Crizotinib (PF-02341066) is a potent inhibitor of c-Met and ALK with IC50 of 11 nM and 24 nM in cell-based assays, respectively.
c-Met [1]
(A549, MDA-MB-231, GTL-16, HT29, 786-O, Colo-205, A498 cells)
ALK [1]
(Karpas299 cells)
11 nM 24 nM
In vitro

PF-2341066 displays similar potency against c-Met phosphorylation in mIMCD3 mouse or MDCK canine epithelial cells with IC50 of 5 nM and 20 nM, respectivly. PF-2341066 shows improved or similar activity against NIH3T3 cells engineered to express c-Met ATP-binding site mutants V1092I or H1094R or the P-loop mutant M1250T with IC50 of 19 nM, 2 nM and 15 nM, respectively, compared with NIH3T3 cells expressing wild-type receptor with IC50 of 13 nM. In contrast, a marked shift in potency of PF-2341066 is observed against cells engineered to express c-Met activation loop mutants Y1230C and Y1235D with IC50 of 127 nM and 92 nM, respectively, compared with wild-type receptor. PF-2341066 also potently prevents the phosphorylation of c-Met in NCI-H69 and HOP92 cells, with IC50 of 13 nM and 16 nM, respectively, which express the endogenous c-Met variants R988C and T1010I, respectively. PF-2341066 is >1,000-fold selective for the VEGFR2 and PDGFRβ RTKs, >250-fold selective for IRK and Lck, and ∼40- to 60-fold selective for Tie2, TrkA, and TrkB, all compared with c-Met. PF-2341066 is 20- to 30-fold selective for RON and Axl RTKs. In contrast, PF-2341066 shows a near-equivalent IC50 of 24 nM against the nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) oncogenic fusion variant of the ALK RTK expressed by the KARPAS299 human anaplastic large cell lymphoma (ALCL) cell line. PF-2341066 inhibits c-Met–dependent neoplastic phenotypes of cancer cells and angiogenic phenotypes of endothelial cells. PF-2341066 suppresses human GTL-16 gastric carcinoma cell growth with IC50 of 9.7 nM. PF-2341066 induces apoptosis in GTL-16 cells with IC50 of 8.4 nM. PF-2341066 inhibits HGF-stimulated human NCI-H441 lung carcinoma cell migration and invasion with IC50 of 11 nM and 6.1 nM, respectively. PF-2341066 inhibits MDCK cell scattering with IC50 of 16 nM. PF-2341066 prevents HGF-stimulated c-Met phosphorylation, cell survival, and Matrigel invasion with IC50 of 11 nM, 14 nM and 35 nM, respectively. In addition, PF-2341066 prevents serum-stimulated HMVEC branching tubulogenesis (formation of vascular tubes) in fibrin gels. [1] PF-2341066 also potently inhibits NPM-ALK phosphorylation in Karpas299 or SU-DHL-1 ALCL cells with an IC50 of 24 nM. PF-2341066 potently prevents cell proliferation, which is associated with G(1)-S-phase cell cycle arrest and induction of apoptosis in ALK-positive ALCL cells with IC50 of 30 nM, but not ALK-negative lymphoma cells. [2] Besides, PF-2341066 prevents osteosarcoma behavior associated with primary tumor growth (i.e., proliferation and survival) as well as metastasis (eg, invasion and clonogenicity). [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BAF3 NXnGb4xUS3m2b4TvfIlkKEG|c3H5 NYqwVGl2PDhiaB?= M1Ple2ROW09? NEC3NJNEgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSUZ|IHPlcIx{KGW6cILld5NqdmdiQVzLJGwyOTl4TTDteZRidnRiY3;lfJBz\XO|aX7nJGVOVDRid3n0bEBKSzVyIH;mJFIvOiEQvF2= MYGyNVU4OjV6OR?=
BAF3 NXP3[mJtS3m2b4TvfIlkKEG|c3H5 MkO2OFghcA>? M4n5XGROW09? MnXaR5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmFHOyClZXzsd{BmgHC{ZYPzbY5oKEWPTEStRWxMKHerdHigTWM2OCCxZjCwMlI5KM7:TR?= NH6wb|EzOTV5MkW4PS=>
Kelly M3TSXGN6fG:2b4jpZ{BCe3OjeR?= NVzVc2dZTE2VTx?= MYLDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDL[YxtgSClZXzsd{BmgHC{ZYPzbY5oKEGOSzDGNVE4PExibYX0ZY51KHerdHigTWM2OCCxZjCwMlQzKM7:TR?= MlPENlE2PzJ3OEm=
SH-SY5Y M1u3XGN6fG:2b4jpZ{BCe3OjeR?= MW\EUXNQ MXPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTTE1UYTW\IHPlcIx{KGW6cILld5NqdmdiQVzLJGYyOTd2TDDteZRidnRid3n0bEBKSzVyIH;mJFAvPTNizszN MXOyNVU4OjV6OR?=
SMS-KCN M3rDeGN6fG:2b4jpZ{BCe3OjeR?= MorlSG1UVw>? NV7DOIg5S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW02VLVvDUkBk\WyuczDlfJBz\XO|aX7nJGFNUyCUMUK3OXEhdXW2YX70JJdqfGhiSVO1NEBw\iByLkmxJO69VQ>? M2[3d|IyPTd{NUi5
BAF3 NEfkXpdEgXSxdH;4bYMhSXO|YYm= MkHjOFghcA>? MnjMSG1UVw>? Mn;RR5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmFHOyClZXzsd{BmgHC{ZYPzbY5oKFSnbD3BUGshf2m2aDDJR|UxKG:oIECuNVkh|ryP M3XsSFIyPTd{NUi5
3T3 NInjVXhHfW6ldHnvckBCe3OjeR?= MoLaNUBp NEfUUFdFVVOR MlPFTY5pcWKrdHnvckBw\iCUT16gZZN{\XO|ZXSgZZMh\3Kxd4ToJIZi[3Sxcj3pcoR2[2WmIHH1eI9xcG:|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDBwMEig{txO NVvrfpY5OjF6MUK0NVQ>
3T3-E NH;hdHJHfW6ldHnvckBCe3OjeR?= M1LWR|EhcA>? NGXlfZlFVVOR NG\rV4hKdmirYnn0bY9vKG:oIGTJSVIh[XO|ZYPz[YQh\3Kxd4ToJIZi[3Sxcj3pcoR2[2WmIHH1eI9xcG:|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDBwNES4JO69VQ>? MXiyNVgyOjRzNB?=
A549 M4rwbmtqdmG|ZTDBd5NigQ>? NEHOVXcyKGh? MX3EUXNQ NVHzNpA3UW6qaXLpeIlwdiCxZjDoeY1idiC{ZXPvcYJqdmGwdDDjMW1GXCCtaX7hd4Uh\XiycnXzd4VlKGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhUEeILXnu[JVk\WRiYYX0c5Bpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhOC5yMEig{txO M4fFb|IyQDF{NEG0
BAF3-BCL M4DQe2Z2dmO2aX;uJGF{e2G7 MU[xJIg> NIj4eZVFVVOR NV\QUpN4UW6qaXLpeIlwdiCxZjDBRmwh[XO|ZYPz[YQh[XNiZ4Lve5RpKG[jY4Tvdk1qdmS3Y3XkJIF2fG:yaH;zdIhwenmuYYTpc44hf2m2aDDJR|UxKG:oIEGuNVU6KM7:TR?= NFvzNnQzOThzMkSxOC=>
HEK293 NX7HXlZUTnWwY4Tpc44hSXO|YYm= NFvnUoIyKGh? Moq2SG1UVw>? MYLJcohq[mm2aX;uJI9nKEG[TDDhd5Nme3OnZDDhd{Boem:5dHig[oFkfG:{LXnu[JVk\WRiYYX0c5Bpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhOC5{OUSg{txO MmTaNlE5OTJ2MUS=
HEK293 NWTOS4hPTnWwY4Tpc44hSXO|YYm= NWDRRodFOSCq MVvEUXNQ MWfJcohq[mm2aX;uJI9nKEmUIHHzd4V{e2WmIHHzJIdzd3e2aDDmZYN1d3JvaX7keYNm\CCjdYTvdIhwe3Cqb4L5cIF1cW:wIIfpeIghUUN3MDDv[kAzNjh6NzFOwG0> NV7WPHBbOjF6MUK0NVQ>
Jurkat MWjGeY5kfGmxbjDBd5NigQ>? MWCxJIg> NHG4XpdFVVOR MYPJcohq[mm2aX;uJI9nKEyFSzDhd5Nme3OnZDDhd{Boem:5dHig[oFkfG:{LXnu[JVk\WRiYYX0c5Bpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhOi55NEGg{txO NUfPOVQ2OjF6MUK0NVQ>
KARPAS299 MmXrT4lv[XOnIFHzd4F6 M2\ZdlEhcA>? NV;nUJBsTE2VTx?= NWDHeZpxUW6qaXLpeIlwdiCxZjDBUGsh[XO|ZYPz[YQh[XNiZ4Lve5RpKG[jY4Tvdk1qdmS3Y3XkJIF2fG:yaH;zdIhwenmuYYTpc44hf2m2aDDJR|UxKG:oIECuNFIh|ryP NIjJ[4ozOThzMkSxOC=>
PAE NX;2UHZQTnWwY4Tpc44hSXO|YYm= NUPkTFJIOSCq NXjYOmFmTE2VTx?= NEnyNHFKdmirYnn0bY9vKG:oIGTST2Ih[XO|ZYPz[YQh[XNiZ4Lve5RpKG[jY4Tvdk1qdmS3Y3XkJIF2fG:yaH;zdIhwenmuYYTpc44hf2m2aDDJR|UxKG:oIECuN|k6KM7:TR?= M3vMZVIyQDF{NEG0
BAF3 NFK2OnlHfW6ldHnvckBCe3OjeR?= MX[yMVMh\A>? NF3nfYlFVVOR NXLJcZpbUW6qaXLpeIlwdiCxZjDUSWwu\nW|ZXSgbY5{fWyrbjDy[YNmeHSxcjDlfJBz\XO|ZXSge4l1cCCLQ{WwJI9nKDFwNkSzJO69VQ>? M3PTUlI{PzR{MkWy
EBC1 NYntdZZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHOO|IhcA>? NV7nVldCTE2VTx?= NVvKfFRqUUN3ME2wMlAzOyEQvF2= NUPmUFltOjN7OUOzNlg>
HCT116 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;0VVczKGh? MmXySG1UVw>? NIS5eG1KSzVyPUG0MlgzKM7:TR?= MlXMNlM6QTN|Mki=
MCF7 MmXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1T3O|czKGh? NGizSphFVVOR NWfoeVRJUUN3ME25MlU5KM7:TR?= Mo\vNlM6QTN|Mki=
MDA-MB-231 M1LIUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPTem93PzJiaB?= M2nEUWROW09? NV3uXmg2UUN3ME2xNE45KM7:TR?= M1TT[VI{QTl|M{K4
NCI-H441 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIf3eGs4OiCq NHHsWGtFVVOR MVfJR|UxRTF5LkK1JO69VQ>? M1S3d|I{QTl|M{K4
NCI-H661 NU[zW2pmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{j4W|czKGh? M2jMb2ROW09? M{WzbWlEPTB;MUGuOFch|ryP NH:wSWYzOzl7M{OyPC=>
SK-MEL-28 M1n3bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV63NkBp MULEUXNQ NUToSVVuUUN3ME2xNE46PyEQvF2= M{XMVFI{QTl|M{K4
SKOV3 M{nZ[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVSzZ4piPzJiaB?= M{K2W2ROW09? MYHJR|UxRTF{Lki1JO69VQ>? MknZNlM6QTN|Mki=
SNU5 MlThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrkdGw4OiCq M3:2bGROW09? Mn;STWM2OD1yLkCxOkDPxE1? NG[4XYszOzl7M{OyPC=>
NCI-H2228 M2DsSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYS3NkBp NYDwNmdrTE2VTx?= MnnUTY5pcWKrdHnvckBw\iCDTFut[pV{cW:wIHTybZZmdiClZXzsJJBzd2yrZnXyZZRqd25id3n0bEBKSzVyIH;mJFAvOTF6IN88US=> MlvJNlQ1OzJ7MEm=
NCI-H3122 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDRbo44OiCq M17HZ2ROW09? MlrVTY5pcWKrdHnvckBw\iCDTFut[pV{cW:wIHTybZZmdiClZXzsJJBzd2yrZnXyZZRqd25id3n0bEBKSzVyIH;mJFAvOTB6IN88US=> NGjWR2gzPDR|MkmwPS=>
NCI-H3122 Mlz5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUC3NkBp MYXEUXNQ NFy2eVNKdmirYnn0bY9vKG:oIFHMT{1nfXOrb36g[JJqfmWwIHPlcIwheHKxbHnm[ZJifGmxbjDpckBpfW2jbjDOR2kuUDNzMkKgZ4VtdHNiaHHyZo9zcW6pIFHMT{BIOTJ4OVGgcZV1[W62IIfpeIghUUN3MDDv[kAxNjZ{MzFOwG0> NVzUVXdoOjR2M{K5NFk>
NCI-H3122 Mmi1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7CbWhXPzJiaB?= NVzsW3Q3TE2VTx?= MXPJcohq[mm2aX;uJI9nKEGOSz3meZNqd25iZILpeoVvKGOnbHygdJJwdGmoZYLheIlwdiCrbjDoeY1idiCQQ1mtTFMyOjJiY3XscJMhcGG{Yn;ybY5oKEGOSzDMNVE6Pk1ibYX0ZY51KHerdHigTWM2OCCxZjCwMlg{QCEQvF2= NUT6VpY5OjR2M{K5NFk>
NIH-3T3 Mmj0T4lv[XOnIFHzd4F6 M3rS[VEhcA>? NH71[WhFVVOR M{LUO2lvcGmkaYTpc44hd2ZiaIXtZY4hf2muZDD0fZBmKEWPTESt[pV{\WRiQVzLJIV5eHKnc4Pl[EBie3Onc4Pl[EBieyCyaH;zdIhwenmuYYTl[EBCVEtibHX2[Ywhf2m2aDDJR|UxKG:oIECuNFgh|ryP NYOxcGVGOjR2M{K5NFk>
NIH-3T3 M3jDfWtqdmG|ZTDBd5NigQ>? MVKxJIg> M4LHb2ROW09? MUDJcohq[mm2aX;uJI9nKGi3bXHuJGVOVDRvZoXz[YQhSUyNIFexNlY6SSCvdYThcpQh\XiycnXzd4VlKGG|c3Xzd4VlKGG|IIDoc5NxcG9vQVzLJIxmfmWuIIfpeIghUUN3MDDv[kAxNjZyNTFOwG0> NVnjO3pzOjR2M{K5NFk>
NIH-3T3 MVXLbY5ie2ViQYPzZZk> NWrVboN7OSCq NX7YfW0xTE2VTx?= NWfFW3V2UW6qaXLpeIlwdiCxZjDoeY1idiCHTVy0MYZ2e2WmIFHMT{BUOTJyNmmgcZV1[W62IHX4dJJme3OnZDDhd5Nme3OnZDDhd{BxcG:|cHjvMWFNUyCuZY\lcEB4cXSqIFnDOVAhd2ZiMD62NlYh|ryP NXn5cVc2OjR2M{K5NFk>
NIH-3T3 M{D1eGtqdmG|ZTDBd5NigQ>? MUmxJIg> MXTEUXNQ NUjkNm1VUW6qaXLpeIlwdiCxZjDoeY1idiCHTVy0MYZ2e2WmIFHMT{BNOTF3MmKgcZV1[W62IHX4dJJme3OnZDDhd5Nme3OnZDDhd{BxcG:|cHjvMWFNUyCuZY\lcEB4cXSqIFnDOVAhd2ZiMT6wNlYh|ryP M3u2T|I1PDN{OUC5
BAF3 MnjpSpVv[3Srb36gRZN{[Xl? NVvDfWhsPzJiaB?= MX\EUXNQ NIPkcndKdmirYnn0bY9vKG:oIF7QUU9CVEtidILhcpNn\WO2ZXSgZZN{\XO|ZXSgZZMh[2WubDDndo94fGhiaX7obYJqfGmxbjD3bZRpKEmFNUCgc4YhOC5yNUGg{txO MW[yOFQ3QDZ|Mh?=
NIH-3T3 MWjLbY5ie2ViQYPzZZk> MY[xJIg> NHjxd|ZKdmirYnn0bY9vKG:oIHj1cYFvKEWPTESt[pV{\WRiQVzLJGYyOTd2TDDteZRidnRiZYjwdoV{e2WmIHHzd4V{e2WmIHHzJJBpd3OyaH:tRWxMKGyndnXsJJdqfGhiSVO1NEBw\iByLkG2OUDPxE1? NXzi[Ip4OjR6MUmxNVY>
NIH-3T3 NGCwVotMcW6jc3WgRZN{[Xl? NHjFPYMyKGh? NHvnOm1KdmirYnn0bY9vKG:oIHj1cYFvKEWPTESt[pV{\WRiQVzLJGMyOTV4WTDteZRidnRiZYjwdoV{e2WmIHHzd4V{e2WmIHHzJJBpd3OyaH:tRWxMKGyndnXsJJdqfGhiSVO1NEBw\iByLkS3PEDPxE1? NGDJe|YzPDhzOUGxOi=>
NIH-3T3 NELUVVVMcW6jc3WgRZN{[Xl? MX:xJIg> MYrJcohq[mm2aX;uJI9nKGi3bXHuJGVOVDRvZoXz[YQhSUyNIFexNlAzWiCvdYThcpQh\XiycnXzd4VlKGG|c3Xzd4VlKGG|IIDoc5NxcG9vQVzLJIxmfmWuIIfpeIghUUN3MDDv[kAyNjF2ODFOwG0> M{TnSFI1QDF7MUG2
NIH-3T3 MYXLbY5ie2ViQYPzZZk> NUXXXlBlOSCq M1HXWmlvcGmkaYTpc44hd2ZiaIXtZY4hTU2OND3meZNm\CCDTFugNVE2OVSrboOgcZV1[W62IHX4dJJme3OnZDDhd5Nme3OnZDDhd{BxcG:|cHjvMWFNUyCuZY\lcEB4cXSqIFnDOVAhd2ZiMz6wN|kh|ryP Mme0NlQ5OTlzMU[=
KARPAS299 NHLRNYhMcW6jc3WgRZN{[Xl? NIHqfpA6OCCvaX6= MoXqSG1UVw>? MXrJcohq[mm2aX;uJI9nKE6STT3meZNm\CCDTFugdIhwe3Cqb4L5cIF1cW:wIHX4dJJme3OnZDD3bZRpKEmFNUCgc4YhOC5zMTFOwG0> M3S4[|I1QTByN{Ww
MKN 45 M360OGtqdmG|ZTDBd5NigQ>? NV\6OlJ4OSCq M2fxUWROW09? MoPGTY5pcWKrdHnvckBw\iClLV3leEBxcG:|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDBwMEKg{txO NH;ZSnAzPDlyMEe1NC=>
A549 MWTDfZRwfG:6aXOgRZN{[Xl? NHfiUXo1QCCq M{TmbGROW09? M163RmlEPTBib3[gOE4xQDRizszN NV;n[lFKOjR7MEC4N|A>
NCI-H1975 MoGzR5l1d3SxeHnjJGF{e2G7 MmTsOFghcA>? NWrmc2Q3TE2VTx?= MljITWM2OCCxZjC3MlU2OSEQvF2= NU\5[pJTOjR7MEC4N|A>
NCI-H1993 MoS2RZBwfG:|aYOgRZN{[Xl? NYT1VZZTOSEQvF2= M4LUT|I1KGh? M2DZT2ROW09? MXfkc4V{KG6xdDDpcoR2[2ViYYDvdJRwe2m| NFq1b20zPDlyMEizNC=>
EBC1 MlXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWP0WJc{PzJiaB?= NYLGbm12TE2VTx?= NIL1co5KSzVyIH;mJFAvODB4OTFOwG0> Mn\PNlQ6ODB6M{G=
NCI-SNU-5 M2DhSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TadmlEPTB;MUC1Mlc2KG6P MlKwV2FPT0WU
SCC-3 M{PSXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvsb4FKSzVyPUO1Ok44PiCwTR?= MX;TRW5ITVJ?
EM-2 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnGXGxKSzVyPU[wNU4{PCCwTR?= NVfu[FRUW0GQR1XS
MHH-CALL-2 MkWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2[5b2lEPTB;NkiyMlU4KG6P MVTTRW5ITVJ?
KM12 Mn;0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1yxcGlEPTB;N{C2Mlkhdk1? NHzkW5BUSU6JRWK=
KINGS-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULPN5JWUUN3ME23OFkvPzVibl2= Mmf3V2FPT0WU
MEG-01 NHXOOphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTh3Nz62OkBvVQ>? NHXGXGxUSU6JRWK=
BV-173 MlPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Moq1TWM2OD1zLkC1PVk4KM7:TR?= MlTDV2FPT0WU
LAMA-84 NWi2bld[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVThUZJwUUN3ME2xMlM5Ojh{IN88US=> NH\HZmZUSU6JRWK=
KARPAS-299 M1Thc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGj5OWJKSzVyPUGuOFA5PjFizszN NE\yVXFUSU6JRWK=
K-562 NFzISWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTFwN{KyOlkh|ryP MWjTRW5ITVJ?
SK-LMS-1 NI\LenJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX:wRmZoUUN3ME2xMlc3QDZ5IN88US=> MmXYV2FPT0WU
ST486 NUHwSXJoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTJwNEOwO|Mh|ryP M4rWN3NCVkeHUh?=
CI-1 M2fRUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PmXmlEPTB;Mj60PVY2QSEQvF2= NXf6dmlkW0GQR1XS
Becker M165[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fkTmlEPTB;ND6yN|k{KM7:TR?= MU\TRW5ITVJ?
GDM-1 MmLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnMNVFKSzVyPUSuNlQ3OTdizszN M2fuTXNCVkeHUh?=
BC-1 NIDNdVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfqdlhOUUN3ME20MlQ6Ojd5IN88US=> M3jReHNCVkeHUh?=
NB14 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrsdHNoUUN3ME20Mlg{PTJ2IN88US=> NF3YVVZUSU6JRWK=
MZ1-PC Ml:0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjSTWM2OD13LkiyNVUyKM7:TR?= M3fLRXNCVkeHUh?=
A498 M4e1VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PXO2lEPTB;Nj6wPFQ4OyEQvF2= MYnTRW5ITVJ?
EW-16 NHHZVppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTZwM{e3O|Mh|ryP NFrOZmNUSU6JRWK=
NALM-6 M3;0XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHHbZdKSzVyPU[uOlg{QDdizszN MlrmV2FPT0WU
EB-3 MnG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHX1SHlKSzVyPUeuNFczOzNizszN MkHzV2FPT0WU
697 M3P5Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPDSYRTUUN3ME25MlI1OzJ7IN88US=> NHPUVW1USU6JRWK=
Ramos-2G6-4C10 M3zHRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTlwNUm4OFIh|ryP NWH5U2JbW0GQR1XS
KNS-81-FD NGH1SmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTlwNkm2OVMh|ryP MYTTRW5ITVJ?
HUTU-80 M3vlOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDlTWM2OD17Lke0OlQzKM7:TR?= NGG4W4JUSU6JRWK=
LS-411N NFzJUZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nzcmlEPTB;MUCuNFU3PyEQvF2= M3LWPHNCVkeHUh?=
RPMI-8402 NUjpdlBOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTqbnZsUUN3ME2xNE4yOTZizszN MkDRV2FPT0WU
KU812 MnzIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrJVG84UUN3ME2xNE4zQTlzIN88US=> MkPjV2FPT0WU
EW-1 M4PMcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTFyLkS0NlUh|ryP NFjzZ2VUSU6JRWK=
NB69 NHHuXYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTFyLkWwOFMh|ryP Mk\EV2FPT0WU
MFH-ino MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTFyLkizNFMh|ryP M171V3NCVkeHUh?=
SK-N-DZ MnrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmr1TWM2OD1zMj6wOFM3KM7:TR?= NFX3TpFUSU6JRWK=
NCI-H720 NYPIeIZuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnjTWM2OD1zMj6xO|A2KM7:TR?= M3y4bnNCVkeHUh?=
HCC1187 M1rpU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvVNXJiUUN3ME2xNk4zODRzIN88US=> MUjTRW5ITVJ?
IST-SL2 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\mSWE2UUN3ME2xNk41QDd{IN88US=> M4nBfHNCVkeHUh?=
KE-37 M2HBU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTGR4dKSzVyPUGyMlc6PjZizszN MoHqV2FPT0WU
HCC1599 NEj2bpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;RcmNKSzVyPUGyMlkxPjlizszN MVrTRW5ITVJ?
A4-Fuk M2PQXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\3TWM2OD1zMj65OVg3KM7:TR?= MVnTRW5ITVJ?
NKM-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfDRXgyUUN3ME2xN{4zQTJ3IN88US=> Mn;ZV2FPT0WU
BE-13 MkTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYO4b3VzUUN3ME2xN{44QTh7IN88US=> MW\TRW5ITVJ?
MV-4-11 NYnrcYxjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLWbXdOUUN3ME2xOE4xOzJ2IN88US=> NIXKdIpUSU6JRWK=
OPM-2 NVTVfWN3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml[4TWM2OD1zND60NFg2KM7:TR?= M3zH[XNCVkeHUh?=
KARPAS-422 M1W1U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPnNFZKSzVyPUG0MlUyOjZizszN Moj5V2FPT0WU
RPMI-8226 NYHwcot5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTF2Lki5NVUh|ryP NVHUSoY4W0GQR1XS
KARPAS-45 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TiOmlEPTB;MUWuO|cyPiEQvF2= NXmye3ZwW0GQR1XS
LC-2 M4fnOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTF4LkG1NFYh|ryP MlvMV2FPT0WU
RL95-2 MnfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3i1XmlEPTB;MU[uN|k4QCEQvF2= M4W5V3NCVkeHUh?=
RPMI-6666 MlfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjBfGRKSzVyPUG2MlkzOTFizszN M3zaVnNCVkeHUh?=
VA-ES-BJ M3\hfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTF5Lke0OVEh|ryP NF25NZdUSU6JRWK=
MONO-MAC-6 NFy4fWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjPNJpKSzVyPUG3Mlk{OTJizszN MorDV2FPT0WU
LAN-6 NVzDV2NyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7kTohKSzVyPUG4Mlc2PTdizszN NH7QeYVUSU6JRWK=
A388 MmSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzuNIRKSzVyPUG5MlMxPTlizszN MVTTRW5ITVJ?
TE-10 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLMTWM2OD1{MD61NlIyKM7:TR?= NUj0SXhnW0GQR1XS
HL-60 NHfzU4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnyeYwyUUN3ME2yNE46ODl7IN88US=> MYLTRW5ITVJ?
MC116 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoD4TWM2OD1{MT63NlIyKM7:TR?= MWHTRW5ITVJ?
NOMO-1 M{TzS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXWwb|lGUUN3ME2yNk43PTZ2IN88US=> NUe4dGJJW0GQR1XS
MRK-nu-1 NGThSIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTmTWM2OD1{Mj65NFc1KM7:TR?= MlfkV2FPT0WU
GR-ST MnuxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\ZTVlCUUN3ME2yN{44PiEQvF2= NYnvbW9lW0GQR1XS
HH M2nWZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TmfWlEPTB;MkSuNFA{KM7:TR?= MULTRW5ITVJ?
NCI-H1963 M3XXdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF:2[GZKSzVyPUK0MlA4QDJizszN NXu4SnNtW0GQR1XS
QIMR-WIL Ml20S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jmXmlEPTB;MkSuPFc4OiEQvF2= Ml\BV2FPT0WU
CGTH-W-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLQTWM2OD1{NT6wO|I{KM7:TR?= NIHjcW1USU6JRWK=
PF-382 MlrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFKzSIZKSzVyPUK3MlIzOjNizszN MmLZV2FPT0WU
ATN-1 Ml3pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTJ5LkO3N|Ih|ryP MoToV2FPT0WU
L-540 M1rtSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTJ5Lk[0OVkh|ryP M1uzcHNCVkeHUh?=
LXF-289 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXKU3JKSzVyPUK3Mlc2OTlizszN M3rDNnNCVkeHUh?=
LS-513 M{\Wb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnqRnFKUUN3ME2yPE4yQDB5IN88US=> Mm\UV2FPT0WU
NCI-H1581 NF[2OWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTNyLkO5O|Yh|ryP NIHkfIxUSU6JRWK=
SW982 NF7UUo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDyTWM2OD1|MD64OVY3KM7:TR?= M{XMbXNCVkeHUh?=
DOHH-2 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HtcWlEPTB;M{GuOVg6OyEQvF2= NXjqVIpQW0GQR1XS
DB M3SwTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYL4V5BsUUN3ME2zN{46PDNzIN88US=> MonkV2FPT0WU
MPP-89 NGH4fVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorKTWM2OD1|ND6xO|U3KM7:TR?= M3rzdnNCVkeHUh?=
LB831-BLC M33ZTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTN2LkWxPFQh|ryP NF;kS4dUSU6JRWK=
NB5 M13kOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH75fmZKSzVyPUO0Mlg2OzVizszN M2jxb3NCVkeHUh?=
GB-1 M2X0fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoH4TWM2OD1|NT6wOFY6KM7:TR?= NV\HTFE{W0GQR1XS
TE-15 M2nJcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXxVItuUUN3ME2zOU4zOjN6IN88US=> NELyb2dUSU6JRWK=
LC4-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTN3LkO4OFch|ryP NXSySHFzW0GQR1XS
NCI-H747 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTN4LkGzOlkh|ryP NVjhNJptW0GQR1XS
NTERA-S-cl-D1 NF6wc4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTN6LkezOFch|ryP MYXTRW5ITVJ?
SK-MM-2 NYn6NGd2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnG0TWM2OD12MD6xNVQ3KM7:TR?= Mn3oV2FPT0WU
CPC-N M2DaV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTR{Lkm5O|Eh|ryP NEXYdHFUSU6JRWK=
ES4 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHrdlhKSzVyPUS0MlQyPTNizszN M3fsfHNCVkeHUh?=
MOLT-4 NFv0e4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{OwVGlEPTB;NEWuNFg2OyEQvF2= M2XIO3NCVkeHUh?=
HT-144 MljRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2P5PWlEPTB;NE[uO|I3KM7:TR?= MXjTRW5ITVJ?
SW872 M2TZZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\u[ZA6UUN3ME20PE4yQTN|IN88US=> NVqxd|BDW0GQR1XS
D-283MED MmrwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTR6LkO1OFIh|ryP M1XW[3NCVkeHUh?=
NCI-H2126 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTR6Lki0O|Yh|ryP MXzTRW5ITVJ?
NCI-SNU-16 NH\wTZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfab3JKSzVyPUS5MlIyPDNizszN MWnTRW5ITVJ?
CESS MnPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTR7LkWwPFgh|ryP M1\0PHNCVkeHUh?=
A101D NGfQXoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;KTWM2OD12OT65O|M3KM7:TR?= MoLhV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo In the GTL-16 model, PF-2341066 reveals the ability to cause marked regression of large established tumors (>600 mm3) in both the 50 mg/kg/day and 75 mg/kg/day treatment cohorts, with a 60% decrease in mean tumor volume over the 43-day administration schedule. In an another study, PF-2341066 displays the ability to completely inhibits GTL-16 tumor growth for >3 months, with only 1 of 12 mice exhibiting a significant increase in tumor growth over the 3-month treatment schedule at 50 mg/kg/day. In the NCI-H441 NSCLC model, a 43% decrease in mean tumor volume is observed at 50 mg/kg/day during the 38-day PF-2341066 administration cycle. In the Caki-1 RCC model, a 53% decrease in mean tumor volume is observed to be associated with decreased volume of each tumor by at least 30% at 50 mg/kg/day during the 33-day PF-2341066 administration cycle. PF-2341066 also reveals near-complete prevention of the growth of established tumors at 50 mg/kg/day in the U87MG glioblastoma or PC-3 prostate carcinoma xenograft models, with 97% or 84% inhibition on the final study day, respectively. In contrast, PF-2341066 p.o. given at 50 mg/kg/day does not significantly inhibit tumor growth in the MDA-MB-231 breast carcinoma model, or the DLD-1 colon carcinoma model. A significant dose-dependent reduction of CD31–positive endothelial cells is observed at 12.5 mg/kg/day, 25 mg/kg/day, and 50 mg/kg/day in GTL-16 tumors, indicating that inhibition of MVD shows a dose-dependent correlation to antitumor efficacy. PF-2341066 displays a significant dose-dependent reduction of human VEGFA and IL-8 plasma levels in both the GTL-16 and U87MG models. Marked inhibition of phosphorylated c-Met, Akt, Erk, PLCλ1, and STAT5 levels is observed in GTL-16 tumors following p.o. administration of PF-2341066.[1] P.o. administration of PF-2341066 to severe combined immunodeficient-Beige mice bearing Karpas299 ALCL tumor xenografts leads to dose-dependent antitumor efficacy with complete regression of all tumors at the 100 mg/kg/d dose within 15 days of initial compound administration. In addition, inhibition of key NPM-ALK signaling mediators, including phospholipase C-gamma, signal transducers and activators of transcription 3, extracellular signal-regulated kinases, and Akt by PF-2341066 are observed at concentrations or dose levels, which correlated with inhibition of NPM-ALK phosphorylation and function.[2] PF-2341066 prevents osteosarcoma behavior associated with primary tumor growth (eg, proliferation and survival) as well as metastasis (eg, invasion and clonogenicity). In nude mice treated with PF-2341066 via oral gavage, the growth and associated osteolysis and extracortical bone matrix formation of osteosarcoma xenografts are prevented by PF-2341066.[3] Treatment of c-MET-amplified GTL-16 xenografts with 50 mg/kg PF-2341066 elicits tumor regression that is associated with a slow reduction in 18F-FDG uptake and decreases expression of the glucose transporter 1, GLUT-1.[4]


Kinase Assay:


+ Expand

Cellular kinase phosphorylation ELISA assays:

Cells are seeded in 96-well plates in media supplemented with 10% fetal bovine serum (FBS) and transferred to serum-free media [with 0.04% bovine serum albumin (BSA)] after 24 h. In experiments investigating ligand-dependent RTK phosphorylation, corresponding growth factors are added for up to 20 min. After incubation of cells with PF-2341066 for 1 h and/or appropriate ligands for the designated times, cells are washed once with HBSS supplemented with 1 mM Na3VO4, and protein lysates are generated from cells. Subsequently, phosphorylation of selected protein kinases is assessed by a sandwich ELISA method using specific capture antibodies used to coat 96-well plates and a detection antibody specific for phosphorylated tyrosine residues. Antibody-coated plates are (a) incubated in the presence of protein lysates at 4°C overnight; (b) washed seven times in 1% Tween 20 in PBS; (c) incubated in a horseradish peroxidase–conjugated anti–total-phosphotyrosine (PY-20) antibody (1:500) for 30 min; (d) washed seven times again; (e) incubated in 3,3′,5,5′-tetramethyl benzidine peroxidase substrate to initiate a colorimetric reaction that is stopped by adding 0.09 N H2SO4; and (f) measured for absorbance in 450 nm using a spectrophotometer.
Cell Research:


+ Expand
  • Cell lines: GTL-16 gastric carcinoma cells and T47D breast carcinoma cells
  • Concentrations: 0-256 nM
  • Incubation Time: 1 hour
  • Method:

    Cells including GTL-16 gastric carcinoma cells and T47D breast carcinoma cells are seeded in 96-well plates in media supplemented with 10% fetal bovine serum (FBS) and transferred to serum-free media [with 0.04% bovine serum albumin (BSA)] after 24 hours. In experiments investigating ligand-dependent RTK phosphorylation, corresponding growth factors are added for up to 20 minutes. After incubation of cells with PF-2341066 for 1 hour and/or appropriate ligands for the designated times, cells are washed once with HBSS supplemented with 1 mM Na3VO4, and protein lysates are generated from cells. Subsequently, phosphorylation of selected protein kinases is assessed by a sandwich ELISA method using specific capture antibodies used to coat 96-well plates and a detection antibody specific for phosphorylated tyrosine residues. Antibody-coated plates are (a) incubated in the presence of protein lysates at 4 °C overnight; (b) washed seven times in 1% Tween 20 in PBS; (c) incubated in a horseradish peroxidase–conjugated anti–total-phosphotyrosine (PY-20) antibody (1:500) for 30 min; (d) washed seven times again; (e) incubated in 3,3,5,5-tetramethyl benzidine peroxidase substrate to initiate a colorimetric reaction that is stopped by adding 0.09 N H2SO4; and (f) measured for absorbance in 450 nm using a spectrophotometer.

    (Only for Reference)
Animal Research:


+ Expand
  • Animal Models: Female or male nu/nu mice bearing NCI-H441,or DLD-1, or MDA-MB-231
  • Formulation: --
  • Dosages: 12.5 mg/kg/day, 25 mg/kg/day, and 50 mg/kg/day
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 9 mg/mL (19.98 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
5% DMSO+30% PEG 300+dd H2O
For best results, use promptly after mixing.

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 450.34


CAS No. 877399-52-5
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03052608 Not yet recruiting Carcinoma, Non-Small-Cell Lung Pfizer March 2017 Phase 3
NCT02838420 Recruiting Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer Hoffmann-La Roche August 2016 Phase 3
NCT02836847 Recruiting Cholangiocarcinoma of the Extrahepatic Bile Duct|Gallbladder Cancer Shanghai Jiao Tong University School of Medicine|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|Ruijin Hospital|RenJi Hospital|Eastern Hepatobiliary Surgery Hospital|Huashan Hospital July 2016 Phase 2
NCT02946359 Recruiting Lung Adenocarcinoma Metastatic Chinese PLA General Hospital July 2016 Phase 2
NCT02679170 Recruiting Non-Small Cell Lung Cancer Pfizer June 2016 --
NCT02767804 Recruiting Non-small Cell Lung Cancer Xcovery Holding Company, LLC June 2016 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Could you tell me whether this product represents the pure R-form of crizotinib, or is the the racemic Crizotinib, so a mixture of the S- and the R-form?

  • Answer:

    Our S1068 Crizotinib is R enantiomer(except batch 05 and 06, they are racemate), and S7505 is S enantiomer.

c-Met Signaling Pathway Map

c-Met Inhibitors with Unique Features

Related c-Met Products

Tags: buy Crizotinib (PF-02341066) | Crizotinib (PF-02341066) supplier | purchase Crizotinib (PF-02341066) | Crizotinib (PF-02341066) cost | Crizotinib (PF-02341066) manufacturer | order Crizotinib (PF-02341066) | Crizotinib (PF-02341066) distributor
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID